S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Theravance Jumps on Glaxo Investment (THRX, GSK)

Photo of Paul Ausick
By Paul Ausick Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Theravance Inc. (NASDAQ: THRX) got a big boost today from a purchase of 10 million additional shares by GlaxoSmithKline plc (NYSE: GSK) at a 7.5% premium to a volume-weighted average share price for the past five trading days thru last Friday. GSK now owns about 26.8% of Theravance, up from Glaxo’s previous stake of 18.3%.

The two companies are working on a new once-a-day drug, Relovair, to treat asthma and chronic obstructive pulmonary disease (COPD). The drug is important to Glaxo as a replacement for its Advair drug which has lost its patent protection in the US and will lose it next year in Europe.

GSK and Theravance are gearing up to file for approval use as a treatment for COPD in the US and Europe for Relovair later this year. Approval for the drug’s use against asthma is also on track for this year, but a US filing may be done later due to the stringency of US rules on once-daily drugs.

Theravance shares are up nearly 16% today at $22.57 in a 52-week range of $12.91-$28.95.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Asthma and COPD Patients Score With Generic Advair Diskus FDA Approval
Jon C. Ogg |

Asthma and COPD Patients Score With Generic Advair Diskus FDA Approval

More and more branded drugs seem to be facing generic competition. The impact might not be so positive for Big…
Innoviva Wins Another Key FDA Approval for Asthma
Chris Lange |

Innoviva Wins Another Key FDA Approval for Asthma

The FDA has approved Innoviva's treatment of asthma and for patients with chronic obstructive pulmonary disease, the company announced, giving…
Theravance Gets FDA Nod on Vibativ
Chris Lange |

Theravance Gets FDA Nod on Vibativ

Theravance Biopharma has announced that the FDA approved its supplemental New Drug Application for Vibativ (telavancin) to expand the product's…
Jon C. Ogg |

Alexza FDA Approval: Coal in the Christmas Stocking?

ThinkstockAlexza Pharmaceuticals, Inc. (NASDAQ: ALXA) is seeing its shareholders get nothing but coal for Christmas this year. The stock is…
What to Expect When Mylan Reports Tuesday
Chris Lange |

What to Expect When Mylan Reports Tuesday

Mylan is scheduled to release its first-quarter financial results before the markets open on Tuesday, and earnings are expected to…
Paul Ausick |

24/7 Wall St. Closing Bell (COST, XOM, AKAM, P, SCCO, MRK, AYI, CBST, AA, INHX, PSOF, IDIX, NFLX, THRX, LTRX)

US markets opened up slightly this morning and have maintained a slight positive tone for most of the day. Today…
Jon C. Ogg |

Death for Dynavax’s Lead Drug Candidate

ThinkstockDynavax Technologies Corp. (NASDAQ: DVAX) is feeling the wrath of the markets after an FDA panel said that there was…
Paul Ausick |

Targacept Gets Mixed Results on Drug Trials (TRGT, AZN)

Development stage drug maker Targacept Inc. (NASDAQ: TRGT) is having its troubles these days. Earlier this month the company said…
Major Biopharma Catalysts on July’s FDA Calendar
Chris Lange |

Major Biopharma Catalysts on July’s FDA Calendar

Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618